An insight into thermodynamic relationship between polymorphic forms of efavirenz

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 15, Issue 2, 2012, Pages 234-251

  Chadha, Renu ^a   Arora, Poonam ^a   Saini, Anupam ^a   Jain, Dharamvir Singh ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID; ACETONITRILE; EFAVIRENZ; METHANOL;

ARTICLE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; CRYSTALLIZATION; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DETERMINATION; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; ENANTIOSELECTIVITY; ENERGY; ENTHALPY; HEATING; SCANNING ELECTRON MICROSCOPY; SOLVENT EFFECT; THERMODYNAMICS; THERMOGRAVIMETRY; TRANSITION TEMPERATURE; X RAY POWDER DIFFRACTION;

EID: 84859449346     PISSN: None     EISSN: 14821826     Source Type: Journal    
DOI: 10.18433/j3j30z     Document Type: Article

References (39)

1. Brittain HG. Polymorphism and solvatomorphism 2007. J Pharm Sci, 2009; 98:1617-1642.
2. Hilfiker R, Blatter F, Raumer MV. Relevance of solid-state properties for pharmaceutical products. In Hilfiker R, editors. Polymorphism: in the pharmaceutical industry. Wiley-vch Verlag GmbH & Co. KGaA, Weinheim, 2006; p 1-19.
3. Ricardo AEC, Teresa MRM, Antonio OLE, Joana CF, Silva MR, Matos BA, Joao C and Eusebio MES. A new insight into pyrazinamide polymorphic forms and their thermodynamic relationships. Crys. Growth & design, 2010; 10: 274-282.
4. Grzesiak AL, Lang M, Kim K, Matzger AJ. Comparison of the four anhydrous polymorphs of carbamazepine and the crystal structure of Form I. J Pharm Sci, 2003; 92:2260-2271.
5. Zhang GGZ, Gu C, Zell MT, Burhardt RT, Munson EJ. Crystallization and transitions of sulfamerazine polymorphs. J Pharm Sci, 2002; 91:1089-1100.
6. Terada K, Kitano H, Yoshihashi Y, Yonemochi E. Quantitative correlation between initial dissolution rate and heat of solution of drug. Pharm Res, 2000; 17:920-924.
7. Beyer T, Day GM, Price SL. The Prediction, Morphology, and Mechanical Properties of the Polymorphs of Paracetamol. J Am Chem Soc, 2001; 123:5086-5094.
8. Aceves-Hernandez JM, Nicolas-Vazquez I, Aceves FJ, Hinojosa-Torres J. Indomethacin polymorphs: Experimental and conformational analysis. J Pharm Sci, 2009; 98:2448-2463.
9. Chauvet A, Masse J, Ribet JP, Bigg D, Autin JM, Maurel JL, Patoiseau JF, Jaud J. Characterization of polymorphs and solvates of 3-(Amino-1-(m- trifluoromethylphenyl)-6-methyl-1H-pyridazin-4- one. J Pharm Sci, 1992; 81:836-841.
10. Okumura T, Otsuka M. A novel standard sample powder preparation method for Quantitative Analysis of Polymorphs. J Pharm Sci, 2005; 94:1013-1023.
11. Pudipeddi M, Serajuddin ATM. Trends in solubility of polymorphs. J Pharm Sci, 2005; 94: 929-937.
12. Radesca L, Maurin M, Rabel S, Moore J. Crystalline efavirenz, 1999; WO 99/64405.
13. Radesca L, Maurin M, Rabel S, Moore J. Crystalline efavirenz, 2004; US 6,673,372 B1.
14. Sharma R, Bhushan HK, Aryan RC, Singh N, Pandya B, Kumar Y. Polymorphic forms of efavirenz and processes for their preparation, 2006; WO 2006/040643 A2.
15. Khanduri HC, Panda AK, Kumar Y. Processes for the preparation of polymorphs of efavirenz, 2006; WO 2006/030299 A1.
16. Reddy BP, Rathnakar K, Reddy RR, Reddy DM, Reddy KSC. Novel polymorphs of efavirenz, 2006; US 2006/0235008.
17. Dova E. Polymorphic forms of efavirenz, 2008; WO 2008/108630 A1.
18. Ravikumar K, Sridhar B. Molecular and crystal structure of efavirenz, a potent and specific inhibitor ofHIV-1 reverse transcriptase, and its monohydrate. Mol Cryst Liq Crystal, 2009; 515:190-198.
19. Indian Pharmacopeia. 5th ed., The Indian Pharmacopoeia Commission. Central Indian Pharmacopoeia Laboratory, Ghaziabad, India, 2007; p 242.
20. Haleblian JK. Characterization of habits and crystalline modification of solids and their pharmaceutical applications. J Pharm Sci. 1975; 64: 1269-1286.
21. Maurin RB, Rowe SM, Blom K, Pierce ME. Kinetics and mechanism of hydrolysis of efavirenz. Pharm Res. 2002; 19: 517-521.
22. Craig DQM, Reading M. Thermal analysis of pharmaceuticals. CRC Press, New York, 2007.
23. Kawakami K. Reversibilty of enantiotropically related polymorphic transformations from a practical viewpoint: Thermal analysis of kinetically reversible/irreversible polymorphic transformations. J Pharm Sci, 2007; 96:982-989.
24. Giron D. Thermal analysis and calorimetric methods in the characterization of polymorphs and solvates. Thermochim Acta, 1995; 248:1-59.
25. Behme RJ, Brooke D. Heat of fusion measurement of a low melting polymorph of carbamazepine that undergoes multiple phase changes during differential scanning calorimetry analysis. J Pharm Sci, 1991; 80:986-990.
26. Urakami K. Characterization of pharmaceutical polymorphs by isothermal calorimetry. Curr Pharm Biotech, 2005; 6: 193-203.
27. Hammond RB, Pencheva K, Roberts KJ, A Auffret. Quantifying solubility enhancement due to particle size reduction and crystal modification: Case study of acetyl salicylic acid. J Pharm Sci, 2007; 96: 1967-1973.
28. Naghibi H, Tamura A, Sturtevant JM. Significant discripancies between van't Hoff and calorimetric enthalpies. Proc Natl Acad Sci USA, 1995; 92: 5597-5599.
29. Liu Y and Sturtevant JM. Significant discripancies between van't Hoff and calorimetric enthalpies. II. Protein Science, 1995; 4: 2559-2561.
30. L. Yu. Inferring thermodynamic stability relationship of polymorphs by melting data. J Pharm Sci, 1995; 84: 966-974.
31. Gu C-H, Grant DJW. Estimating the relative stability of polymorphs and hydrates from heat of solution and solubility data. J Pharm Sci, 2001; 90:1277-1287.
32. Foppoli A, Sangalli ME, Maroni A, Gazzaniga A, Caira MR, Giordano F. Polymorphism of NCX4016, an NO-releasing derivative of acetylsalicylic acid. J Pharm Sci, 2004; 93:521-53.
33. Greman M, Vrecer F, Meden A. Some physicochemical properties of doxazosin mesylate polymorphic forms and its amorphous state. J Therm Ana and Cal, 2002; 68:373-387.
34. Chauvet A, Masse J, Ribet JP, Bigg D, Autin JM, Maurel JL, Patoiseau JF, Jaud J. Characterization of polymorphs and solvates of 3-Amino-1-(m- trifluoromethylphenyl)-6-methyl-1H-pyridazin-4- one. J Pharm Sci, 1992; 81:836-841.
35. Ghodbane S, McCauley JA. Study of the polymorphism of 3-(((3-(2-(7-chloro-2-quinolinyl)-(E)-ethenyl)phenyl)((3-(dimethylamino-3-oxoprpyl)thio)methyl)-thio)prpanoic acid (MK571) by DSC, TG, XRPD and solubility measurements. Int J Pharm, 1990; 59:281-286.
36. Ashizawa K. Polymorphism and crystal structure of 2R, 4S, 6-Fluoro-2-methyl-spiro [chroman-4, 4′-imidazoline]-2′, 5-dione (M79175). J Pharm Sci, 1999; 78:256-260.
37. Grzesiak AL, Lang M, Kim K, Matzger AJ. Comparison of the four anhydrous polymorphs of carbamazepine and the crystal structure of Form I. J Pharm Sci, 2003; 92:2260-2271.
38. Chang L-C, Caira MR, Guillory JK. Solid state characterization of dehydroepiandrosterone. J Pharm Sci, 1995; 84:1169-1179.
39. Griesser UJ, Burger A, Mereiter K. The polymorphic drug substances of the European Pharmacopeia. Part 9. Physicochemical properties and crystal structure of acetazolamide crystal forms. J Pharm Sci, 1997; 86:352-358.